Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P970004/S460

InterStim Therapy System, Verify Evaluation System (SNS Urinary Neurostimulator 97800), (SNS Urinary Neurostimulator I

Medtronic Neuromodulation · Decision date Oct 29, 2026

MEDTECHLEDGER EXPLANATIONP970004/S460

What did the FDA decide?

The FDA recorded decision OK30 on 2026-10-29 for PMA supplement P970004/S460, submitted by Medtronic Neuromodulation as a 30-Day Notice for a process change affecting manufacturing, sterilization, packaging or supplier operations. The supplement sits under P970004, whose listed title covers the InterStim Therapy System and Verify Evaluation System, including the SNS Urinary Neurostimulator 97800. The device category is an electrical implantable stimulator for incontinence, with gastroenterology and urology specialties and product code EZW.

The recorded statement describes battery-line process controls rather than a new approval of the whole system: enhanced operator verification of the FactoryWorks step and recorded battery pre-weight, pre- and post-weight out-of-control action plans, software and human machine interface updates that reject batteries above the established final-fill reasonable limit, dedicated white work-in-progress trays, an isopropyl alcohol wipe for residual electrolyte, and removal of Ball Press and Button Press certification prerequisites for ram changes on Medium Rate Line 2, with supervisors and engineers retaining certification responsibility. No documents were provided, so the underlying supplement filing and any clinical or labeling effect remain unknown.

The listed date is in the future relative to typical publication timelines, and the source does not state whether the notice was accepted without further review or what follow-up applies. Whether these manufacturing changes alter device performance or labeling cannot be determined from the record.

FDA approval order statement

1. Enhanced operator verification of the applicable FactoryWorks processing step and recorded battery pre-weight.2. Addition of pre-weight and post-weight out-of-control action plans to the applicable Process Operation Descriptions.3. Software and Human Machine Interface updates that will automatically reject batteries with fill weights above the established final-fill reasonable limit.4. Introduction of dedicated white work-in-progress trays to distinguish electrolyte-filled batteries and improve line clearance, handling, and traceability.5. Use of an isopropyl alcohol wipe to remove residual electrolyte from battery surfaces before subsequent processing.6. Removal of the Ball Press and Button Press certification prerequisites from the Ball and Button Press Ram Change procedure, allowing Medium Rate Line 2 operators to qualify for press ram changes by completing only the ram-change procedure while supervisors and engineers retain responsibility for operator certification
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Gastroenterology, Urology
Decision date
Oct 29, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P970004/S460
Regulatory pathway
PMA supplement
Product code
EZW
Decision code
OK30
Decision date
Oct 29, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Stimulator, electrical, implantable, for incontinence.

Product code
EZW
FDA device class
3

For the original device and its historical approval scope, see PMA P970004. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P970004 · Original PMA

    MEDTRONIC INTERSTIM THERAPY SYSTEM FOR URINARY CONTROL

  2. P970004/S458 · Related supplement

    InterStim Therapy System Verify Evaluation System

  3. P970004/S460 received

    Application receipt date recorded by FDA.

  4. P970004/S457 · Related supplement

    InterStim Therapy System, Verify Evaluation System

  5. P970004/S459 · Related supplement

    InterStim Therapy System, Verify Evaluation System

  6. P970004/S460 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P970004. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P970004

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Medtronic Neuromodulation

Headquarters
Not reported
Brand website
medtronic.com
FDA applicant address
7000 Central Ave., NE, Minneapolis, MN, 55432

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records